Pharmacological actions of isoprostane metabolites and phytoprostanes in human and bovine pulmonary smooth muscles

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 76, Issue 1, 2007, Pages 57-64

  Liu, Caiqiong ^a   Tazzeo, Tracy ^a   Guy, Alexandre ^b   Durand, Thierry ^b   Janssen, Luke J ^a  

^a ST JOSEPH S HOSPITAL   (Canada)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

13,14 DIHYDRO 15 KETOISOPROSTANE; 15 KETOISOPROSTANE; 2,3 DINOR 5,6 DIHYDROISOPROSTANE; 2,3 DINORISOPROSTANE; 20 CARBOXY 2,3,4,5 TETRANOR 15 OXO 5,6,13,14 TETRAHYDROISOPROSTANE; DRUG METABOLITE; ISOPROSTANE; ISOPROSTANE DERIVATIVE; PHYTOPROSTANE; UNCLASSIFIED DRUG;

AIRWAY; AIRWAY CONSTRICTION; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; COW; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN TISSUE; LUNG; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; SMOOTH MUSCLE;

ANIMALS; CATTLE; CYCLOPENTANES; DINOPROST; FATTY ACIDS, UNSATURATED; HUMANS; ISOMETRIC CONTRACTION; ISOPROSTANES; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; TRACHEA;

BOS TAURUS;

EID: 33846021323     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2006.08.005     Document Type: Article

References (41)

1. Baraldi E., Carraro S., Alinovi R., Pesci A., Ghiro L., Bodini A., et al. Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations. Thorax 58 (2003) 505-509
2. Baraldi E., Ghiro L., Piovan V., Carraro S., Ciabattoni G., Barnes P.J., et al. Increased exhaled 8-isoprostane in childhood asthma. Chest 124 (2003) 25-31
3. Montuschi P., Corradi M., Ciabattoni G., Nightingale J., Kharitonov S.A., and Barnes P.J. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am. J. Respir. Crit. Care Med. 160 (1999) 216-220
4. Wood L.G., Fitzgerald D.A., Gibson P.G., Cooper D.M., and Garg M.L. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids 35 (2000) 967-974
5. Ciabattoni G., Davi G., Collura M., Iapichino L., Pardo F., Ganci A., et al. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 162 (2000) 1195-1201
6. Collins C.E., Quaggiotto P., Wood L., O'Loughlin E.V., Henry R.L., and Garg M.L. Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis. Lipids 34 (1999) 551-556
7. Montuschi P., Kharitonov S.A., Ciabattoni G., Corradi M., van Rensen L., Geddes D.M., et al. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax 55 (2000) 205-209
8. Biernacki W.A., Kharitonov S.A., and Barnes P.J. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 58 (2003) 294-298
9. Kostikas K., Papatheodorou G., Psathakis K., Panagou P., and Loukides S. Oxidative stress in expired breath condensate of patients with COPD. Chest 124 (2003) 1373-1380
10. Montuschi P., Collins J.V., Ciabattoni G., Lazzeri N., Corradi M., Kharitonov S.A., et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 162 (2000) 1175-1177
11. Pratico D., Basili S., Vieri M., Cordova C., Violi F., and FitzGerald G.A. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am. J. Respir. Crit. Care Med. 158 (1998) 1709-1714
12. Cracowski J.L., Cracowski C., Bessard G., Pepin J.L., Bessard J., Schwebel C., et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 164 (2001) 1038-1042
13. Hazbun M.E., Hamilton R., Holian A., and Eschenbacher W.L. Ozone-induced increases in substance P and 8-epi-prostaglandin F2 alpha in the airways of human subjects. Am. J. Respir. Cell Mol. Biol. 9 (1993) 568-572
14. Bachi A., Zuccato E., Baraldi M., Fanelli R., and Chiabrando C. Measurement of urinary 8-Epi-prostaglandin F2 alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers. Free Radic. Biol. Med. 20 (1996) 619-624
15. Chiabrando C., Valagussa A., Rivalta C., Durand T., Guy A., Zuccato E., et al. Identification and measurement of endogenous beta-oxidation metabolites of 8-epi-Prostaglandin F2alpha. J. Biol. Chem. 274 (1999) 1313-1319
16. Obata T., Tomaru K., Nagakura T., Izumi Y., and Kawamoto T. Smoking and oxidant stress: assay of isoprostane in human urine by gas chromatography-mass spectrometry. J. Chromatogr. B, Biomed. Sci. Appl. 746 (2000) 11-15
17. Montuschi P., Curro D., Ragazzoni E., Preziosi P., and Ciabattoni G. Anaphylaxis increases 8-iso-prostaglandin F2alpha release from guinea- pig lung in vitro. Eur. J. Pharmacol. 365 (1999) 59-64
18. Janssen L.J. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am. J. Physiol. Lung Cell Mol. Physiol. 280 (2001) L1067-L1082
19. Helli P.B., Catalli A., and Janssen L.J. The bronchodilators 8-iso-prostaglandin E(2) and prostaglandin E(2) induce K(+) current suppression via thromboxane A(2) receptors in porcine tracheal smooth muscle. Eur. J. Pharmacol. 501 (2004) 179-184
20. Janssen L.J., Premji M., Netherton S., Catalli A., Cox G., Keshavjee S., et al. Excitatory and inhibitory actions of isoprostanes in human and canine airway smooth muscle. J. Pharmacol. Exp. Ther. 295 (2000) 506-511
21. Janssen L.J., and Tazzeo T. Involvement of TP and EP3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature. J. Pharmacol. Exp. Ther. 301 (2002) 1060-1066
22. Janssen L.J., Premji M., Netherton S., Coruzzi J., Lu-Chao H., and Cox P.G. Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. Br. J. Pharmacol. 132 (2001) 127-134
23. Tazzeo T., Miller J., and Janssen L.J. Vasoconstrictor responses, and underlying mechanisms, to isoprostanes in human and porcine bronchial arterial smooth muscle. Br. J. Pharmacol. 140 (2003) 759-763
24. Catalli A., Zhang D., and Janssen L.J. Receptors and signaling pathway underlying relaxations to isoprostanes in canine and porcine airway smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 283 (2002) L1151-L1159
25. Basu S. Metabolism of 8-iso-prostaglandin F2alpha. FEBS Lett. 428 (1998) 32-36
26. Granstrom E., and Samuelsson B. On the metabolism of prostaglandin F 2 in female subjects. II. Structures of six metabolites. J. Biol. Chem. 246 (1971) 7470-7485
27. Roberts L.J., Moore K.P., Zackert W.E., Oates J.A., and Morrow J.D. Identification of the major urinary metabolite of the F2-isoprostane 8- iso-prostaglandin F2alpha in humans. J. Biol. Chem. 271 (1996) 20617-20620
28. Awad J.A., Morrow J.D., Takahashi K., and Roberts L.J. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J. Biol. Chem. 268 (1993) 4161-4169
29. Chiabrando C., Rivalta C., Bagnati R., Valagussa A., Durand T., Guy A., et al. Identification of metabolites from type III F2-isoprostane diastereoisomers by mass spectrometry. J. Lipid Res. 43 (2002) 495-509
30. Imbusch R., and Mueller M.J. Formation of isoprostane F(2)-like compounds (phytoprostanes F(1)) from alpha-linolenic acid in plants. Free Radic. Biol. Med. 28 (2000) 720-726
31. Loeffler C., Berger S., Guy A., Durand T., Bringmann G., Dreyer M., et al. B1-phytoprostanes trigger plant defense and detoxification responses. Plant Physiol. 137 (2005) 328-340
32. Guy A., Durand T., Roland A., Cormenier E., and Rossi J.C. Total synthesis of ent-15(RS)-2,3-dinor-5,6-dihydro-8-epi-PGF2alpha. Tetrahedron Lett. 39 (1998) 6181-6184
33. Durand T., Guy A., Henry O., Vidal J.P., Rossi J.C., Rivalta C., Valagussa A., and Chiabrando C. Total syntheses of four metabolites of 15-F2t-Isoprostane. Eur. J. Org. Chem. 4 (2001) 809-819
34. Durand T., Henry O., Guy A., Roland A., Vidal J.P., and Rossi J.C. Radical cyclization: towards the syntheses of tetranor metabolites of 15-F2t-isoprostane. Tetrahedron 59 (2003) 2485-2495
35. Durand T., Cracowski J.L., Guy A., and Rossi J.C. Syntheses and preliminary pharmacological evaluation of the two epimers of the 5-F2t-isoprostane. Bioorg. Med. Chem. Lett. 11 (2001) 2495-2498
36. El Fangour S., Guy A., Despres V., Vidal J.P., Rossi J.C., and Durand T. Total synthesis of the eight diastereomers of the syn-anti-syn phytoprostanes F1 types I and II. J. Org. Chem. 69 (2004) 2498-2503
37. Catalli A., and Janssen L.J. Augmentation of bovine airway smooth muscle responsiveness to carbachol, KCl, and histamine by the isoprostane 8-iso-PGE2. Am. J. Physiol. Lung Cell Mol. Physiol. 287 (2004) L1035-L1041
38. Cracowski J.L., Camus L., Durand T., Devillier P., Guy A., Hardy G., et al. Response of rat thoracic aorta to F2 -isoprostane metabolites. J. Cardiovasc. Pharmacol. 39 (2002) 396-403
39. Hou X., Roberts L.J., Taber D.F., Morrow J.D., Kanai K., Gobeil Jr. F., et al. 2,3-Dinor-5,6-dihydro-15-F(2t)-isoprostane: a bioactive prostanoid metabolite. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281 (2001) R391-R400
40. Traidl-Hoffmann C., Mariani V., Hochrein H., Karg K., Wagner H., et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J. Exp. Med. 201 (2005) 627-636
41. Zhang Y., Tazzeo T., Hirota S., and Janssen L.J. Vasodilatory and electrophysiological actions of 8-iso-prostaglandin E2 in porcine coronary artery. J. Pharmacol. Exp. Ther. 305 (2003) 1054-1060